The functions of TRPA1 and TRPV1: moving away from sensory nerves

Abstract

Introduction

The transient receptor potential vanilloid 1 and ankyrin 1 (TRPV1 and TRPA1, respectively) channels are members of the TRP superfamily of structurally related, non-selective cation channels that is divided into seven families: TRPC (Canonical), TRPN (no mechanoreceptor potential C), TRPM (Melastatin), TRPML (Mucolipin), TRPP (Polycystin), TRPA (Ankyrin) and TRPV (Vanilloid), each present in several species across the animal kingdom (Pedersen et al., 2005; Clapham, 2007). TRP channels have many different physiological roles, ranging from purported roles as store-operated calcium channels (e.g. TRPC3, TRPC7; Riccio et al., 2002; Kaznacheyeva et al., 2007), to roles in thermo- (e.g. A1, M8, V1, V4; Caterina et al., 1997; Güler et al., 2002; Peier et al., 2002; Story et al., 2003), mechano- (e.g. A1, C1, V1, V4; Liedtke et al., 2003; Walker et al., 2003; Corey et al., 2004; Maroto et al., 2005) and chemo-sensation (e.g. A1, M8, V1; Peier et al., 2002; Bandell et al., 2004; Andersson et al., 2008). All TRP channels are tetramers formed by subunits with six transmembrane domains and cation-selective pores, which frequently show high calcium permeability (Latorre et al., 2009).

Whilst all seven families have wide roles in many physiological and pathophysiological processes, TRPV1 and TRPA1 will be the specific focus of this review. Both TRPV1 and TRPA1 play an integral role in pain (Bevan and Andersson, 2009; Fernandes et al., 2011) and neurogenic inflammation (Geppetti et al., 2008) via sensory nerve activation. In fact, 97% of TRPA1-expressing sensory neurons express TRPV1, while 30% of TRPV1-expressing neurons express TRPA1 (Story et al., 2003). Both TRPV1 and TRPA1 channels are calcium-permeable, and, although their subunits have not been shown to form a heterotetramer channel, they may form a complex on the plasma membrane of sensory neurons. This enables TRPV1 to influence intrinsic characteristics of the TRPA1 channel, including voltage–current relationships and its open probability at negative holding potentials (Staruschenko et al., 2010). Similarly, Salas et al. (2009) have shown that the features of neuronal TRPA1 are not duplicated in cells expressing only TRPA1 and, instead, can be restored only when TRPA1 and TRPV1 channels are coexpressed. Moreover, both TRPV1 and TRPA1 are integrators of a range of noxious stimuli, and TRPV1 and TRPA1 agonists are able, at least in part, to heterologously desensitize TRPV1 and TRPA1 pathways (Ruparel et al., 2008). Overall, based on evidence such as that described above, it may well be that TRPV1 and TRPA1 are ‘partners in crime’ in the activation of sensory nerves.

The role of these TRP channels in pain and neurogenic inflammation have, to date, been very well covered by previous authors (e.g. Bevan and Andersson, 2009; Cortright and Szallasi, 2009; Stucky et al., 2009; Fernandes et al., 2011), which reflects the enormity of the role that these channels play in sensory nerve function at both a central and peripheral level. However, there is accumulating evidence that TRPV1 and TRPA1 have functional roles away from sensory nerve activity, which this review aims to address. In order to substantiate a role for these non-sensory nerve TRP channels in either normal physiology or disease, several criteria must be fulfilled: (1) TRPV1/TRPA1 expression should be demonstrated in these tissues at the gene and protein level; (2) the receptors should be functional, that is, showing evidence of calcium permeability; and (3) a role in either physiological or pathophysiological functions should be demonstrated. In discussing these other functions, the imperative importance of TRPV1 and TRPA1 in pain and neurogenic inflammation cannot and should not be diminished. Furthermore, it is entirely possible that the TRPV1 and TRPA1 activity away from sensory nerves may indirectly affect pain and neurogenic inflammation.

TRPV1

The vanilloid TRP channels are divided into six members – 1 to 6. However, only TRPV1 from the TRPV subfamily is actually activated by vanilloids, including capsaicin, the pungent component of chilli peppers. The capacity of capsaicin to activate sensory nerves was determined by Jancsó in the 1960s (Jancsóet al., 1967). However, it was 15 years later that the presence of a capsaicin receptor in the plasma membrane of sensory nerves was recognized by Szolcsányi and Jancsó-Gábor (1975). In 1997 came perhaps the most significant advance in TRPV1 research, when the mouse TRPV1 receptor was cloned by Caterina et al. (1997) [later cloned in humans (Hayes et al., 2000) and guinea-pigs (Savidge et al., 2002)]. With this major advance in the understanding of TRPV1 at a molecular level came the confirmation that heat >43°C and pH <5.9 also activate TRPV1 (Tominaga et al., 1998). Furthermore, the generation of TRPV1 knockout mice and a comprehensive analysis of the phenotype of the animals confirmed a pivotal role for this receptor in noxious heat sensation in vivo (Caterina et al., 2000). A variety of exogenous and endogenous activators of TRPV1 have since been identified (see Table 1).

Table 1

Agonists and modulators

In this context, it is important to mention that the TRPV1 receptor undergoes desensitisation after repeated administration of, or prolonged exposure to, capsaicin (Szolcsányi et al., 1975) or resinaferatoxin (Szolcsányi et al., 1990). The receptor not only becomes desensitized to other activators of the same receptor, but the TRPV1 pathway heterologously desensitizes responses to TRPA1 agonists and vice versa (Ruparel et al., 2008). The mechanisms underlying homologous and heterologous desensitization appear to be distinct with capsaicin-induced desensitization being calcium-dependent but heterologous desensitization being calcium-independent (Ruparel et al., 2008). In addition, high doses of capsaicin selectively destroy C- and Aδ sensory nerves, thereby completely preventing nerve activation (Szallasi et al., 1995). Clearly, this means that capsaicin-induced desensitization/nerve destruction cannot be used to examine TRPV1-specific down-stream effects on physiological/pathophysiological processes. However, it can be used to show that capsaicin-induced desensitization via TRPV1 has a functional effect upon a cell or tissue.

TRPA1

Although TRPA1 was identified slightly later than its TRPV1 counterpart, its discovery took a comparable course. The effects of the classic TRPA1 agonist, mustard oil (the active component being allyl isothiocyanate), were identified much earlier (e.g. Koltzenburg and McMahon, 1986) than the receptor itself, with this compound commonly being used to induce neurogenic inflammation, in a similar manner to capsaicin. TRPA1 was first cloned by Jaquemar et al. (1999), although its expression on neurons was not reported until 2003 when Story et al. identified it as a receptor for noxious cold temperature. However, the association between TRPA1 and mustard oil was later confirmed in 2005 when Jordt and colleagues not only established TRPA1 as the mustard oil receptor but also for tetrahydrocannabinol, leading the way into a plethora of research into further possible TRPA1 agonists (see Table 1). Indeed, concomitant with the groundbreaking generation of TRPA1 knockout mice (Bautista et al., 2006) came the finding that TRPA1 mediates the effects of acrolein (2-propenal), present in tear gas, vehicle exhaust, tobacco products and byproducts of chemotherapeutic agents. Unlike the situation with TRPV1 knockout mice, an examination of the phenotype of TRPA1 knockouts regarding a role for this receptor in noxious temperature sensation has proved controversial. Two independent knockout animals have been generated (Bautista et al., 2006; Kwan et al., 2006). The portion of the gene knocked out was the fifth and sixth transmembrane domains (required for ion conduction) in both cases. However, Bautista et al. (2006) reported normal responses to cold temperatures both in vivo and in vitro in TRPA1 knockout mice. On the other hand, knockouts in the Kwan et al. (2006) study displayed a clear functional deficit to cold stimulation. A discussion of the reasons underlying these differences is beyond the scope of this review, but it remains to be seen whether TRPA1 is truly a thermosensor channel.

TRPV1 and TRPA1 expression

Peripheral expression

Within the periphery, recent evidence has located TRPV1 and TRPA1 on a variety of non-neuronal tissues. In fact, the list of possible sites of expression is becoming so great that to discuss all in turn would be outside of the scope of this article. Tables 2 and ​and33 list the peripheral non-neuronal cells on which TRPV1 and TRPA1 have been located by RT-PCR for RNA expression and/or immunohistochemical staining Western blot for protein expression. From this extensive list, it is clear to see that the advent of molecular biology techniques in this field a decade ago has revolutionized our potential understanding of the possible functions of these TRP channels. However, as mentioned previously, evidence that receptor mRNA or protein is present in a tissue should be substantiated by evidence that the channel is functional. Therefore, the following section will address that studies that have provided evidence of TRPV1/TRPA1 functionality in brain or peripheral sites.

Table 2

TRPV1 expression

Table 3

TRPA1 expression

Receptor functionality

Although TRPV1/TRPA1 channel expression has been shown in a wide variety of tissues, evidence of functionality has not yet been demonstrated for all of these. Therefore, this section will solely concentrate on cell types where both a molecular and functional presence has been confirmed. One of the first cell types in which functionality was first identified is epidermal keratinocytes. Inoue et al. (2002) demonstrated that both capsaicin and acidification produced elevations in the intracellular calcium concentration in cultured human epidermal keratinocytes. Furthermore, these increases were inhibited by the TRPV1 antagonist, capsazepine (Inoue et al., 2002). Similarly, treatment of human skin fibroblasts with capsaicin induced significant changes in the membrane current and the intracellular calcium level that were antagonized by capsazepine (Kim et al., 2006). More recently, TRPA1 agonists have also been shown to activate calcium currents in both keratinocytes (cold, allyl isothiocyanate and mustard oil; Atoyan et al., 2009) and fibroblasts (cold, allyl isothiocyanate and cinnemaldehyde; Hu et al., 2010). This trend is carried forth with a multitude of other cells, as summarized in Table 2.

It is therefore clear to this point that TRPV1 and TRPA1 are expressed and functional away from sensory nerves. Nevertheless, this does not mean that the channels have similar sensitivities. However, a comparison of the sensitivity of channels expressed on sensory nerves and other tissues regarding agonist stimulation is extremely difficult to extract from the literature. The only study that to date has directly compared neuronal and non-neuronal TRPV1 responses is that by Kark et al. (2008) in vascular tissue. In the vasculature, capsaicin has biphasic effects: at lower concentrations up to 10 nM, dilations are observed in response to neuronal TRPV1 activation. Conversely, at higher capsaicin concentrations between 0.1 and 1 µM, vasoconstriction is observed in response to non-neuronal TRPV1 activation.

In other cell types, capsaicin increased the intracellular calcium concentration of rat vagal neurons within a capsaicin concentration range of 0.1–10 µM (Marsh et al., 1987) and increased the intracellular calcium concentration of human and murine adipocytes within a capsaicin concentration range of 0.01–1 µM (Zhang et al., 2007). The sensitivity of neuronal and non-neuronal TRPV1 to capsaicin activation in these studies therefore looks similar. However, it is impossible to directly compare studies due to differences in experimental conditions, including species differences (rat vs. mouse/human, respectively, for the Marsh and Zhang studies). Thus, the study by Kark et al. (2008) provides the only evidence to date that there may be differences in sensitivity between neuronal and non-neuronal forms of the receptor. The sensitivity of TRPA1 on sensory nerves compared with TRPA1 on other tissues is also very difficult to discuss, as no study has directly compared the same agonist in each type of tissue across a concentration range. Thus, any difference in sensitivity remains to be seen.

Role in physiological or pathophysiological function

From the previous sections, it is clear that the range of cell types expressing functional TRPV1 and TRPA1 is very diverse. As such, it is not surprising that the associated functions of these receptors are also complex. Physiological or pathophysiological effects of non-neuronal TRPV1 and TRPA1 have been implicated in inflammation, infection and immunity, the cardiovascular system and in conditions such as obesity. Meanwhile, neuronal TRPV1 in the brain may have functions in neurogenesis (Jin et al., 2004) and thermoregulation (Jancsó-Gábor et al., 1970b), amongst others. The following sections will discuss the effects of TRPV1 and TRPA1 in the brain as well as non-neuronal TRPV1 and TRPA1 within the context of different physiological/pathophysiological systems. In doing so, the possible significance of these TRP channels away from sensory nerves will be highlighted.

In the brain

As mentioned previously, TRPV1 is expressed throughout the brain and, moreover, these TRPV1 channels appear to be functional upon agonist stimulation. Indeed, downstream of channel activation, Jancsô and Wollemann (1977) have reported that capsaicin stimulates adenylate cyclase activity in the rat cerebral cortex in vitro. Furthermore, direct injection of capsaicin into the preoptic area of the anterior hypothalamus (Jancsó-Gábor et al., 1970b) or i.c.v. region (Dib, 1982) of the rat brain causes hypothermia, suggesting a role for this channel in thermoregulation. Hypothermia is associated with a fall in rectal and hypothalamic temperature, an increased cutaneous temperature (Dib, 1982) and tail skin vasodilation (Jancsó-Gábor et al., 1970a). Vice versa, rats desensitized by hypothalamic injections of high concentrations of capsaicin lose their ability to thermoregulate against overheating of their bodies and respond with an enhanced hyperthermia to strong sensory stimuli such as repeated pinching of the tail (Jancsó-Gábor et al., 1970a). Similarly, systemic administration of TRPV1 antagonists such as AMG517 (Gavva et al., 2007b), AMG0347 (Steiner et al., 2007) and A-425619 (Gavva et al., 2007a) causes an increase in body temperature within approximately 1 h of treatment. However, antagonist-induced hyperthermia may not be mediated by hypothalamic TRPV1 as peripherally-restricted antagonists still have the capacity to cause an increase in body temperature (Tamayo et al., 2008).

In inflammation, infection and immunity

A physiological/pathophysiological role for non-neuronal TRPV1/TRPA1 is perhaps nowhere more apparent than in the case of inflammation, infection and immunity. However, it is important to note that although the effects of these TRP channels are non-neuronal, it is evident that they may well impact indirectly upon pain and/or neurogenic inflammation. As mentioned previously, keratinocytes functionally express both TRPV1 and TRPA1. These cells play an important role in maintaining the integrity of the immune response in skin as well as stimulating cutaneous inflammation via prostanoid and cytokine release (Gröne et al., 2002). TRPV1 activation by capsaicin causes an increase in COX2 expression in human keratinocytes with a concomitant increase in PGE₂ levels in vitro (Southall et al., 2003). An increase in IL-8 is also observed (Southall et al., 2003). Similarly, treatment of human keratinocytes with the TRPA1 agonist, icilin, has been shown to increase the expression of pro-inflammatory ILs (IL-1α and IL-1β; Atoyan et al., 2009) as well altering the expression of genes involved in the control of keratinocyte proliferation, differentiation and cell cycle regulation (Atoyan et al., 2009). Stimulation of inflammatory mediator release by TRPV1/TRPA1 agonists from keratinocytes could well have a significant effect upon sensory nerves that have a high density in skin, especially as PGE₂ and IL-1 are known to sensitize and/or activate sensory nerve endings (Schaible and Schmidt, 1988; Binshtok et al., 2008). This is therefore a prime example of how non-neuronal TRPV1/TRPA1 may interact with sensory nerves to affect pain and neurogenic inflammation.

As well as keratinocytes, peripheral blood mononuclear cells (PBMCs) are also directly affected by TRPV1/TRPA1 activation. For example, PBMCs undergo apoptosis when stimulated with capsaicin or resinaferatoxin, an effect that is reversed by the TRPV1 antagonist, AM630 (Saunders et al., 2007). In relation to TRPA1, the cinnamaldehyde derivative, 2′-hydroxycinnamaldehyde has been shown to inhibit nitric oxide release and NF-κB activation in macrophages that have been stimulated with LPS (the cell wall component of Gram-negative bacteria; Lee et al., 2005). Similarly, cinnemaldehyde inhibits IL-1β and TNFα release from human monocytes and macrophages that have been stimulated by LPS (Chao et al., 2008). A concomitant reduction of the release of reactive oxygen species from the macrophages is also observed (Chao et al., 2008). It would therefore appear that the effects of TRPV1 and TRPA1 in terms of their direct effects on inflammatory cells appear to be in part anti-inflammatory.

There are various other cells involved in immunity that respond to TRPV1 and TRPA1 activation including bone marrow-derived dendritic cells, where capsaicin leads to dendritic cell maturation and an increase in antigen presentation (Basu and Srivastava, 2005). Furthermore, with regard to TRPA1, cinnamaldehyde has been shown to cause a dose-dependent suppression of the lymphoproliferation in LPS-treated mouse splenocytes (Koh et al., 1998). The same study also showed that the exposure of thymocytes to cinnamaldehyde accelerated T-cell differentiation from CD4 and CD8 double-positive cells to CD4 or CD8 single-positive cells (Koh et al., 1998).

It is therefore clear that TRPV1 and TRPA1 are expressed, functional and are active within cells relevant to inflammation, infection and immunity. Most of the aforementioned studies have been carried out in vitro and so the precise influences of these effects in an in vivo setting are, as yet, far from clear. However, what it is clear from other studies is that TRPV1 at least plays a paradoxical role in inflammation in vivo, for example, exacerbating inflammation in arthritis and yet in experimentally induced sepsis, TRPV1 null mice demonstrate elevated levels of pathological markers in comparison with wild-type mice (Alawi and Keeble, 2010). It cannot be ruled out at this stage that this is due to differing effects of neuronal and non-neuronal TRPV1 channels.

Role in the vasculature

TRPV1 and TRPA1 have been shown to control vascular responses either by the well-established neurogenic response that is mediated by sensory nerves (Geppetti et al., 2008) or via a direct effect on vascular tissue (Kark et al., 2008; Earley et al., 2009). However, the non-neuronal mechanisms involved in mediating vasodilatation and oedema formation following TRPV1 and TRPA1 activation in vivo are unclear. Both endothelial cells and smooth muscle cells express a variety of membrane ion channels to control Ca²⁺ influx and membrane potential, including the expression of TRPV1 and TRPA1 channels on endothelial cells (Yao and Garland, 2005; Earley et al., 2009) and TRPV1 expression on vascular smooth muscle cells (Kark et al., 2008; Cavanaugh et al., 2011), as described in Table 1. Thus, there is clearly the potential for non-neuronal TRPV1 and TRPA1 to contribute to vasculature control.

TRPV1 on endothelial cells has been shown to regulate the expression and secretion of endothelial cell-derived CGRP, which affords protective effects on endothelial cells (Luo et al., 2008). Furthermore, CGRP is a potent vasodilator (Brain et al., 1985), and this CGRP may therefore impact upon blood pressure. Indeed, TRPV1 activation on sensory nerves also causes CGRP release, leading to a profound decrease in vascular tone (Zygmunt et al., 1999). On the other hand, TRPV1 expressed on vascular smooth muscle appears to cause vasoconstriction. Kark et al. (2008) have shown that capsaicin triggers transient vasoconstriction in isolated pressurised rat skeletal muscle arterioles, which is not abolished by endothelial cell removal or denervation in vivo, indicating the vasoconstriction was mediated by a direct effect of TRPV1 on vascular smooth muscle. Keeble and Brain (2006) have also demonstrated vasoconstrictor responses to capsaicin, albeit in the mouse synovial membrane. More recently, Cavanaugh et al. (2011) have demonstrated vasoconstriction in response to capsaicin in mouse ear arterioles. Interestingly, as mentioned previously, it has also been suggested that capsaicin has biphasic effects on the vasculature: at lower concentrations, capsaicin (up to 10 nM) evokes vasodilation in skin due to sensory nerve activation, whereas higher concentrations (0.1–1 µM) elicit substantial constrictions in skeletal muscle arterioles due to non-neuronal TRPV1 stimulation (Kark et al., 2008). It is unclear whether this difference is due to receptor sensitivity (as discussed earlier with respect to receptor functionality) or a difference in TRPV1 receptor density in the two tissues. Furthermore, it is not entirely clear whether, in order to achieve vasoconstriction, the vasodilator effect of capsaicin first needs to be counteracted. However, it is possible that highly localised TRPV1 activation by endogenous activators means that vasoconstriction or vasodilation are triggered entirely separately, as opposed to treatment with exogenous capsaicin when all TRPV1 is likely to be affected simultaneously.

TRPV1 may also play a role in vascular responses during chronic hypoxia where up-regulation of the TRPV1 gene and protein is observed (Y.X. Wang et al., 2008). Chronic hypoxia has been shown to enhance the ability of human pulmonary artery smooth muscle cells to proliferate and to increase resting levels of cytosolic calcium and capacitative calcium entry with both effects being inhibited in a dose-dependent manner by the TRPV1 antagonist, capsazepine (Y.X. Wang et al., 2008). These results therefore suggest that TRPV1 on smooth muscle may be a critical pathway or mediator in chronic hypoxia-induced vascular changes.

Research into TRPA1 in the vasculature is still in an early phase although mustard oil has been shown to trigger vasodilatation in rat cerebral arteries via a mechanism that appears to involve TRPA1 expressed on endothelial cells (Earley et al., 2009). Mustard oil-induced vasodilation was not mediated by nitric oxide or prostanoids, rather by calcium-activated potassium channels on endothelial cells and inwardly rectifying potassium channels on arterial myocytes. Furthermore, the responses were inhibited by the TRPA1 antagonist, HC-030031 (Earley et al., 2009).

It is therefore clear that non-neuronal TRPV1 and TRPA1 both have the potential to play a role in the physiology or pathophysiology of the vasculature. TRPV1 in general has been shown to play a role in hypertension (Li and Wang, 2003), cardiac ischaemia (Wang and Wang, 2005) and cardiovascular shock (Akabori et al., 2007). However, the relative contribution of neuronal and non-neuronal TRPV1 to these effects is, as yet, far from clear. In the case of TRPA1, the physiological relevance of TRPA1 on sensory nerves in the vasculature has only just been elucidated (Pozsgai et al., 2010), and so we still have a long way to go with our understanding of this channel.

Obesity and thermogenesis

Obesity is one of the most significant health issues in western society due to the morbidity associated with this condition that is increasing in prevalence. Thus, a significant amount of research has been generated to understand its underlying causes and means of treating/preventing the condition. It is known that obesity is induced by the hypertrophy of adipocytes and the recruitment of new adipocytes from precursor cells. These processes are dependent on the regulation of adipocyte differentiation. The TRPV1 receptor is very interesting in this respect as capsaicin has been shown to inhibit adipocyte differentiation in vitro by activation of AMP-activated protein kinase (Hwang et al., 2005). Furthermore, Hsu and Yen (2007) have shown that treatment of preadipocytes with capsaicin decreases the number of normal adipocytes and increases the number of early apoptotic and late apoptotic cells in a dose-dependent manner. Furthermore, treatment of adipocytes with capsaicin was shown to decrease the quantity of intracellular triglycerides and glycerol-3-phosphate dehydrogenase activity (Hsu and Yen, 2007), both biomarkers of adipogenesis.

As with the previous physiological/pathophysiological conditions discussed, it is not known how significantly non-neuronal TRPV1 receptors contribute to the overall effects of TRPV1 activation. However, the overall effect of TRPV1 modulation in obesity is stark. For example, both animal (Zhang et al., 2007) and human (Ohnuki et al., 2001) data have indicated that the consumption of capsaicin- or non-pungent capsiate-containing foods is correlated with a reduced incidence of obesity. Similarly, oral administration of capsaicin alone also suppresses body fat accumulation in mice (Ohnuki et al., 2001), and dietary capsaicin can reduce obesity-induced insulin resistance and hepatic stenosis in mice fed a high fat diet (Kang et al., 2010). Moreover, TRPV1-mediated changes in thermogenesis may have the potential to impact upon obesity, possibly through changes in expression of thermogenic uncoupling proteins, as seen in response to chronic treatment of rats with capsiates (Masuda et al., 2003).

In recent years, a role for TRPV1 in thermoregulation has also been identified which may, at least in part, be due to changes in thermogenesis (for review, see Romanovsky et al., 2009). For many years, capsaicin has been known to cause a centrally mediated hypothermia in mice (Jancsó-Gábor et al., 1970b). In contrast, its intragastric administration enhances thermogenesis and heat diffusion (Masamoto et al., 2009). Similarly, the jejunal administration of non-pungent capsaicin analogues was shown to increase energy expenditure via direct activation of TRPV1 located on intestinal extrinsic nerves (Kawabata et al., 2009). Interestingly, some TRPV1 antagonists cause hyperthermia, associated with increased thermogenesis (Gavva et al., 2007a) through a peripheral mechanism (Tamayo et al., 2008), whilst TRPV1 gene knock down does not affect body temperature in mice (Tóth et al., 2011). and TRPV1 knockout mice exhibit a normal basal body temperature (Steiner et al., 2007). Although this clearly shows a homeostatic role for TRPV1 in thermoregulation, it is beyond the scope of this review to discuss the mechanism underlying TRPV1 antagonist-induced hyperthermia as there is, to date, no direct evidence that it is mediated by non-neuronal TRPV1. It will be extremely interesting in the future to determine whether the mechanism underlying role of TRPV1 in thermoregulation is intrinsically linked with the aforementioned role for TRPV1 in obesity.

Conclusion

To conclude, it is now clear that the roles of TRPV1 and TRPA1 discussed in this review extend far beyond sensory nerves. Not only are TRPV1 and TRPA1 receptors expressed in other neuronal and non-neuronal tissues, but they also exhibit functionality and they are of potential physiological/pathophysiological relevance. It is clear that we still have a great deal to learn about these receptors away from sensory nerves, especially in relation to their precise function in vivo. We also need to find out a great deal more about their influence upon pain and neurogenic inflammation as it is entirely possible that they are intrinsically related. Progress in this field would be greatly enhanced by selective knockout/knockdown of TRPV1/TRPA1 on sensory nerves and/or other specific cell types. Furthermore, it would be interesting to determine whether TRPV1 antagonists, or the currently available TRPA1 antagonists, have any relative specificity for these TRP channels on different cell types. Finally, it remains to be seen whether different modes of activation of TRPV1 and TRPA1 have potentially differing importance depending on the site of TRP channel expression. We eagerly await these answers.

Acknowledgments

Glossary

References